Given the known false-negative finding of CA-125 for patients with stage I ovarian cancer (hence its failure as a screening biomarker), 4 recent studies, 2 in ovarian cancer screening and 2 in patients exhibiting symptoms, have proposed lower thresholds for elevated CA-125 level. This evidence concerns the gene MUC16 and ovarian carcinoma.